Plasminogen activator inhibitor-1 4G/5G polymorphism in breast cancer patients and its association with tissue PAI-1 levels and tumor severity
- 31 December 2006
- journal article
- Published by Elsevier in Thrombosis Research
- Vol. 117 (5) , 487-492
- https://doi.org/10.1016/j.thromres.2005.03.025
Abstract
No abstract availableKeywords
This publication has 34 references indexed in Scilit:
- Pleiotropic functions of plasminogen activator inhibitor-1Journal of Thrombosis and Haemostasis, 2005
- Complex of urokinase‐type plasminogen activator with its type 1 inhibitor predicts poor outcome in 576 patients with lymph node–negative breast carcinomaCancer, 2004
- Urokinase-type plasminogen activator (uPA) and its inhibitor PAI-1: novel tumor-derived factors with a high prognostic and predictive impact in breast cancerThrombosis and Haemostasis, 2004
- Plasminogen activator inhibitor-1 and tumour growth, invasion, and metastasisThrombosis and Haemostasis, 2004
- Plasminogen activator inhibitor-1 detaches cells from extracellular matrices by inactivating integrinsThe Journal of cell biology, 2003
- The Serpins Are an Expanding Superfamily of Structurally Similar but Functionally Diverse ProteinsJournal of Biological Chemistry, 2001
- Five Frequent Polymorphisms of the PAI-1 GeneArteriosclerosis, Thrombosis, and Vascular Biology, 1997
- Increase in levels of plasminogen activator and type-1 plasminogen activator inhibitor in human breast cancer: Possible roles in tumor progression and metastasisThrombosis Research, 1991
- Plasminogen activator inhibitors: hormonally regulated serpinsMolecular and Cellular Endocrinology, 1990
- cDNA cloning of human plasminogen activator-inhibitor from endothelial cells.Journal of Clinical Investigation, 1986